To the full analysis
Pharma Mar stock: growth
PHM.MCPharma Mar reported $245.32M in revenue for fiscal 2025, up 26.6% on the prior year, down 3.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.8%
per year from 2006 to 2025, per share 5.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −3.9% | 1.4% | 5.8% |
| Revenue per share | −2.7% | 2.1% | 5.9% |
| Earnings | −11.4% | 27.5% | no data |
| Earnings per share | −10.5% | 28.1% | no data |
| Free cash flow | −30.8% | 37.0% | no data |
| Free cash flow per share | −30.0% | 37.9% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $84.48M | −$53.91M | −$67.34M |
| 2007 | $94.7M | −$56.14M | −$58.75M |
| 2008 | $116.64M | −$48.46M | −$39.51M |
| 2009 | $136.73M | −$31.18M | −$31.36M |
| 2010 | $170.1M | −$13.67M | −$27.69M |
| 2011 | $168.97M | −$1.52M | −$8.13M |
| 2012 | $153.17M | $7.31M | $4.75M |
| 2013 | $155.66M | $12.55M | $15.79M |
| 2014 | $164.76M | $14.53M | $13.22M |
| 2015 | $213.66M | $7.3M | $2.08M |
| 2016 | $200.5M | −$26.69M | −$16.08M |
| 2017 | $198.72M | −$29.64M | −$6.79M |
| 2018 | $179.69M | −$6.13M | −$20.74M |
| 2019 | $95.1M | −$10.17M | −$33.3M |
| 2020 | $299.14M | $152.1M | $305.77M |
| 2021 | $254.68M | $102.9M | $19.81M |
| 2022 | $217.57M | $54.69M | $32.65M |
| 2023 | $175.25M | $1.26M | −$32.58M |
| 2024 | $193.76M | $28.95M | −$10.51M |
| 2025 | $245.32M | $83.09M | $48.48M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.